Molecular biology of central nervous system tumors

Current Opinion in Oncology

Volumn 10, Issue 3, 1998, Pages 179-185

  Rempel, Sandra A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P21;

ANGIOGENESIS; CANCER GENETICS; CANCER INVASION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0031804683     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199805000-00002     Document Type: Review

References (69)

1. Sherr CJ: Cancer cell cycles, Science 1996, 274:1672-1677. •• An excellent review of the genes involved in the restriction point control of the cell cycle.
2. Lala P, Angelov L, Provias J, Guha A: Growth factors and nervous system tumors. In Cancer of the Nervous System. Edited by Black P, Loeffler JS, Cambridge, MA: Blackwell Scientific Publications; 1997:744-772.
3. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang H-JS: A • common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996, 56:5097-5086. A biologic analysis of the effects of a constitutively active truncated EGFR on the proliferation and apoptosis of glioblastoma cells.
4. Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An H-X, Niederacher D, Wechsler W, Reifenberger G: Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exper Neurol 1996, 55:822-831.
5. Rempel SA, Louis D, Seizinger B: Tumor suppressor genes in human nervous system neoplasia. In Cancer of the Nervous System. Edited by Black P, Loeffler JS, Cambridge, MA: Blackwell Scientific Publications: 1997:773-789.
6. Dudas SP, Rempel SA: Development molecular genetics, and gene therapy of glial tumors. In The Practical Management of Low Grade Primary Brain Tumors. Edited by Rock JP, Rosenblum ML, Shaw E, Cairncross G, Philadelphia: Lippincott-Raven Publishers 1998, in press.
7. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP: Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996, 149:29-35.
8. Nagane M, Huang H-JS, Cavenee WK: Advances in the molecular genetics of gliomas. Curr Opinion Oncol 1997, 9:215-222.
9. Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M: Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 1996, 78:287-293.
10. Schmidt EE, Ichimura K, Messerle KR, Goike HM, Collins VP: Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br J Cancer 1997, 75:2-8.
11. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang H-JS: Replacement of the P16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995, 55:1351-1354.
12. Hama S, Sadatomo T, Yoshioka H, Kurisu K, Tahara E, Naruse I, Heike Y, Saijo N: Transformation of human glioma cell lines with the p16 gene inhibits cell proliferation. Anticancer Res 1997, 17:1933-1938.
13. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto • T, Ueki K, Louis DN: Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996, 55:1026-1031. An investigation indicating that p16 deletions may have a differentially advantageous effect on deregulating the cell cycle.
14. Barker FG, Chen P, Furman F, Aldape KD, Edwards MSB, Israel MA: p16 deletion and mutation analysis in human brain tumors. J Neurooncol 1997, 31:17-23.
15. Reifenberger G, Ichimura K, Reifenberger J, Elkahloun AG, Meltzer PS, Collins VP: Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res 1996, 56:5141-5145.
16. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995, 55:4833-4836.
17. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072.
18. Dirks PB, Hubbard SL, Murakami M, Rutka JT: Cyclin and cyclin-dependent kinase expression in human astrocytoma cell lines. J Neuropathol Exp Neurol 1997, 56:291-300.
19. Stuart ET, Haffner R, Oren M, Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 1995, 14:5638-5645.
20. Stuart ET, Kioussi C, Aguzzi A, Gruss P: PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995, 1:207-214.
21. Kubbutat MHG, Jones SN, Vousden KH: Regulation of p53 stability by MDM2. Nature 1997, 387:299-303.
22. Haupt Y, Maya R, Kazaz A, Oren M: MDM2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
23. Kondo S, Morimura T, Barnett GH, Kondo Y, Peterson JW, Kaakaji R, Takeuchi J, Toms SA, Liu J, Werbel B, Barna BP: The transforming activities of MDM2 in cultured neonatal rat astrocytes. Oncogens 1996, 13:1773-1779.
24. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression • of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 1997, 56:180-185. A study of 29 primary glioblastomas and 27 secondary glioblastomas associating the amplification of MDM2 in a significant proportion of primary glioblastomas.
25. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997, 75:1269-1278.
26. Giese A, Westphal M: Glioma invasion in the central nervous system. Neurosurgery 1996, 39:235-252.
27. Uhm JH, Dooley NP, Villemure J-G, Yong VW: Mechanisms of glioma invasion: role of matrix-metalloproteinases. Can J Neurol 1997, 24:3-15.
28. Werb Z: ECM and cell surface proteolysis: regulating cellular ecology. •• Cell 1997, 91:439-442. An outstanding review of enzyme-substrate and ligand-receptor interactions in signaling pathways regulating cell-cell and cell-matrix interactions.
29. Haugland HK, Tynes BB, Tynes O-B: Adhesion and migration of human • glioma cells are differently dependent on extracellular matrix molecules. Anticancer Res 1997, 17:1035-1043. A study investigating the adhesive and migratory behavior of glioma cells on different ECM molecules and the ECM-integrin interactions modulating these mechanisms.
30. Mahesparan R, Tynes BB, Edvardsen K, Haugeland HK, Cabrera IG, Lund-Johansen M, Engebraaten O, Bjerkvig R: Role of high molecular weight extracellular matrix proteins in glioma cell migration. Neuropathol Appl Neurobiol 1997, 23:102-112.
31. Tysnes BB, Larsen LF, Ness GO, Mahesparan R, Edvardsen K, Garcia-Cabera I, Bjerkvig R: Stimulation of glioma-cell migration by laminin and inhibition by anti-α3 and anti-β1 integrin antibodies. Int J Cancer 1996, 67:777-784.
32. Goldbrunner RH, Haugland HK, Klein CE, Kerkau S, Roosen K, Tonn J-C: ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions. Anticancer Res 1996, 16:3679-3688.
33. Ohnishi T, Arita N, Hiraga S, Taki T, Izumoto S, Fukushima Y, Hayakawa T: Fibronectin-mediated cell migration promotes glioma cell invasion through chemokine activity. Clin Exp Metastasis 1997, 15:538-546.
34. Friedlander DR, Zagzag D, Shiff B, Cohen H, Allen JC, Kelly PJ, Grumet M: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves αv and β1 integrins. Cancer Res 1996, 56:1939-1947.
35. Bjerkvig R, Lund-Johansen M, Edvardsen K: Tumor cell invasion and angiogenesis in the central nervous system. Curr Opinion Oncol 1997, 9:223-229.
36. Previtali S, Quattrini A, Nemni R, Truci G, Ducati A, Wrabetz L, Canal N: α6β4 and α6β1 integrins in astrocytomas and other CNS tumors. J Neuropathol Exp Neurol 1996, 55:456-465.
37. Mohanam S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, • Gokaslan ZL, Sawaya R, Rao JS: In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 1997, 14:1351-1359. A study of the effects of antisense uPA receptor on glioma cell adhesion, migration, and MMP-2 expression.
38. Reyes-Mugica M, Rieger-Christ K, Ohgaki H, Ekstrand BC, Helie M, • Kleinman G, Yahanda A, Fearon ER, Kleihues P, Reale MA: Loss of DCC expression and glioma progression. Cancer Res 1997, 57:382-386. A study of DCC expression in glioma progression and correlation of DCC loss with secondary glioblastomas.
39. Steck PA, Pershouse MA, Jasser SA, Yung A, Lin H, Ligon AH, Langford • LA, Baumgard ML, Mattier T, Davis T, et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362. Identification and characterization of a candidate tumor-suppressor gene that is mutated in glioma, prostate, kidney, and breast carcinoma cell lines and tumor specimens.
40. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, • Rodgers L, McCombie R, et al.: PTEN, a putative tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. Identification and characterization of a candidate tumor-suppressor gene that is mutated in glioma, prostate, and breast carcinoma cell lines and tumor specimens and xenografts.
41. Gutmann DH, Giordano MJ, Fishback AS, Guha A: Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997, 49:267-270.
42. Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubic M: Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery 1997, 40:578-587.
43. Hitotsumatsu T, Iwaki T, Kitamoto T, Mizoguchi M, Suzuki SO, Hamada Y, • Fukui M, Tateishi J: Expression of neurofibromatosis 2 protein in human brain tumors: an immunohistochemical study. Acta Neuropathol 1997, 93:225-232. An immunohistochemical analysis of merlin expression in CNS tumors and normal cells. Merlin was localized to the inner cell membrane at cell-cell adhesion sites, and loss of merlin was demonstrated for schwannomas and fibroblastic and transitional meningioma subtypes.
44. Sage EH: Terms of attachment: SPARC and tumorigenesis. Nature Med 1997, 3:144-146.
45. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao, S, Chou P, • Bouck NP: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996, 56:5684-5691. A study indicating that the increased angiogenesis observed in glioblastoma is due in part to the loss of a tumor-suppressor gene on chromosome 10 that regulates the secretion of the angiogenesis inhibitor thrombospondin.
46. Guerin C, Laterra J: Regulation of angiogenesis In malignant gliomas. In Regulation of Angiogenesis. Edited by Goldberg ID, Rosen EM, Basel, Switzerland: Birkenäuser Verlag; 1997:47-64.
47. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML: Vascular endothelial growth-factor expression and vascular density as prognostic markers of survival in patients with low grade astrocytomas. Neurosurgery 1998, in press.
48. Provias J, Claffey K, delAguila L, Lau N, Feldkamp M, Guha A: Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997, 40:1016-1026.
49. Lothe RA, Karhu R, Mandahl N, Mertens F, Saeter G, Heim S, Børresen-Dale A-L, Kallioniemi O-P: Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res 1996, 56:4778-4781.
50. Rosenberg JE, Lisle DK, Burwick JA, Ueki K, Von Deimling A, Mohrenweiser HW, Louis DN: Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. Oncogene 1996, 13:2483-2485.
51. Chattopadhyay P, Rathore A, Mathur M, Sarkar C, Mahapatra AK, Sinha S: Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumors. Oncogene 1997, 15:871-875.
52. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, •• Lichter P: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: towards a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997, 94:14719-14724. An outstanding study combining comparative genomic hybridization and focused molecular genetic analyses of 19 benign, 21 atypical, and 19 anaplastic meningiomas to identify chromosomal aberrations involved in meningioma progression.
53. Antinheimo J, Haapasalo H, Haltia M, Tatagiba M, Thomas S, Brandis A, Sainio M, Carpen O, Samii M, Jääskeläinen J: Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 1997, 87:610-614.
54. Tse JYM, Ng H-K, Lau K-M, Lo K-W, Poon W-S, Huang DP: Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. Human Pathol 1997, 28:779-785.
55. Boström J, Mühlbauer A, Reifenberger G: Deletion mapping of the short arm of chromosome 1 identifies a common region of deletion distal to D1S496 in human meningiomas. Acta Neuropathol 1997, 94:479-485.
56. Niedermayer I, Feiden W, Henn W, Steilen-Gimbel H, Steudel W-I, Zang KD: Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol 1997, 56:879-886.
57. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sörensen N, Berthold F, Henk B, Schmandt N, et al.: Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997, 57:2085-2088.
58. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G: Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumours of the central nervous system. Cancer Res 1997, 57:2581-2585.
59. Xie J, Johnson RL, Zhang X, Bare JW, Waldman FM, Cogen PH, Menon AG, Warren RS, Chen LC, Scott MP, Epstein EH Jr: Mutations of the PATCHED gene in several types of sporadic extracutaneous tumours. Cancer Res 1997, 57:2369-2372.
60. Vorechovsky I, Tingby O, Hartman M, Stromberg B, Nister M, Collins VP, Toftgard R: Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 1997, 15:361-366.
61. Wechsler DS, Shelly CA, Petroff CA, Dang CV: MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 1997, 57:4905-4912.
62. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, von Deimling A, Poustka A: DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted on malignant brain tumors. Nat Genet 1997, 17:32-39.
63. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG, Scott RJ, Merlo A: New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26. Oncogene 1997, 15:997-1000.
64. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C, Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, et al.: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997, 90:809-819.
65. Wienecke R, Guha A, Maize JC, Heideman RL, DeClue JE, Gutmann DH: Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 1997, 42:230-235.
66. Hamilton RL, Pollack IF: The molecular biology of ependymomas. Brain Pathol 1997, 7:807-822.
67. Provias JP, Becker LE: Cellular and molecular pathology of medulloblastoma. J Neurooncol 1996, 29:35-43.
68. Black P, Carroll R, Zhang J: The molecular biology of hormone and growth factor receptors in meningiomas. Acta Neurochir 1996, 65:50-53.
69. Merzak A, Pilkington GJ: Molecular and cellular pathology of intrinsic brain tumours. Cancer Metastas Rev 1997, 16:155-177.